Gastric damage related to radioactive iodine treatment and the protective effect of amifostine.

Basit Öğe Kaydı
dc.authoridCelik, Mehmet/0000-0001-7364-370X
dc.authorwosidCelik, Mehmet/AAA-8773-2021
dc.contributor.authorSezer, Atakan
dc.contributor.authorCelik, Mehmet
dc.contributor.authorUsta, Ufuk
dc.contributor.authorAltun, Gulay Durmus
dc.date.accessioned2024-06-12T11:13:21Z
dc.date.available2024-06-12T11:13:21Z
dc.date.issued2017
dc.departmentTrakya Üniversitesien_US
dc.description.abstractIntroduction: The aim of this study was to evaluate the gastric damage related to high dose radioactive iodine treatment during thyroid cancer treatment in an experimental rat model and evaluate histopathologically the radioprotective effect of amifostine. Methods and findings: 40 adult rats were enrolled into the study. Radioactive iodine treatment with 30 mCi/kg I-131 was applied via orogastric tube simulating radioiodine ablation treatment (RAI) in thyroid cancer in all rats. After RAI subjects were divided into 2 groups: Group Orogastric RAI (Group OG, n: 20): Rats received no radioprotective agent but serum physiologic. Group Amifostine RAI (Group AP, n: 20): Rats received 200 mg/kg amifostine intraperitoneally 30 minutes before I-131 application. On the 1st, 3rd, 5th and 7th days of experiment rats were sacrificed for histopathological evaluation. Gastric tissues were excised and tissue damage was assessed by using histopathological scoring. Total pathology score revealed a significant change on the 7th day. The subjects in Group OG had histopathological changes, while only one subject in Group AP was found to have pathologic changes (X2=39.7 df (28), p=0.04). The common histopathological findings were striking mucosal and intraepithelial leucocytic infiltration together with thinning of the mucosa, regenerative changes, and reactive atypia. Conclusions: RAI treatment causes gastric mucosal injury and amifostine was found to decrease radioactive iodine treatment related gastric damage.en_US
dc.identifier.endpage3710en_US
dc.identifier.issn0970-938X
dc.identifier.issn0976-1683
dc.identifier.issue8en_US
dc.identifier.startpage3705en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/23512
dc.identifier.volume28en_US
dc.identifier.wosWOS:000403454800069en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherScientific Publishers Indiaen_US
dc.relation.ispartofBiomedical Research-Indiaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectRadioactive Iodine Treatmenten_US
dc.subjectGastric Damageen_US
dc.subjectAmifostineen_US
dc.subjectThyroiden_US
dc.subjectDifferentiated Thyroid-Canceren_US
dc.subjectDose Radioiodine Therapyen_US
dc.subjectGraves-Diseaseen_US
dc.subjectSalivary-Glandsen_US
dc.subjectI-131 Ablationen_US
dc.subjectCarcinomaen_US
dc.subjectRadioprotectionen_US
dc.titleGastric damage related to radioactive iodine treatment and the protective effect of amifostine.en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu